S&P 500   4,244.07 (+0.35%)
DOW   32,985.01 (-0.05%)
QQQ   357.79 (+0.81%)
AAPL   172.72 (+0.19%)
MSFT   317.06 (+1.17%)
META   304.89 (+1.31%)
GOOGL   134.49 (+1.56%)
AMZN   125.98 (+1.01%)
TSLA   257.97 (+4.64%)
NVDA   436.23 (+0.24%)
NIO   8.71 (+1.16%)
BABA   83.74 (-0.95%)
AMD   102.16 (+2.08%)
T   14.54 (-1.62%)
F   11.90 (-1.41%)
MU   67.68 (-0.22%)
CGC   0.75 (+10.17%)
GE   108.12 (+0.33%)
DIS   78.90 (-0.80%)
AMC   8.18 (+4.20%)
PFE   33.09 (-2.39%)
PYPL   58.15 (+1.48%)
NFLX   374.52 (-0.59%)
S&P 500   4,244.07 (+0.35%)
DOW   32,985.01 (-0.05%)
QQQ   357.79 (+0.81%)
AAPL   172.72 (+0.19%)
MSFT   317.06 (+1.17%)
META   304.89 (+1.31%)
GOOGL   134.49 (+1.56%)
AMZN   125.98 (+1.01%)
TSLA   257.97 (+4.64%)
NVDA   436.23 (+0.24%)
NIO   8.71 (+1.16%)
BABA   83.74 (-0.95%)
AMD   102.16 (+2.08%)
T   14.54 (-1.62%)
F   11.90 (-1.41%)
MU   67.68 (-0.22%)
CGC   0.75 (+10.17%)
GE   108.12 (+0.33%)
DIS   78.90 (-0.80%)
AMC   8.18 (+4.20%)
PFE   33.09 (-2.39%)
PYPL   58.15 (+1.48%)
NFLX   374.52 (-0.59%)
S&P 500   4,244.07 (+0.35%)
DOW   32,985.01 (-0.05%)
QQQ   357.79 (+0.81%)
AAPL   172.72 (+0.19%)
MSFT   317.06 (+1.17%)
META   304.89 (+1.31%)
GOOGL   134.49 (+1.56%)
AMZN   125.98 (+1.01%)
TSLA   257.97 (+4.64%)
NVDA   436.23 (+0.24%)
NIO   8.71 (+1.16%)
BABA   83.74 (-0.95%)
AMD   102.16 (+2.08%)
T   14.54 (-1.62%)
F   11.90 (-1.41%)
MU   67.68 (-0.22%)
CGC   0.75 (+10.17%)
GE   108.12 (+0.33%)
DIS   78.90 (-0.80%)
AMC   8.18 (+4.20%)
PFE   33.09 (-2.39%)
PYPL   58.15 (+1.48%)
NFLX   374.52 (-0.59%)
S&P 500   4,244.07 (+0.35%)
DOW   32,985.01 (-0.05%)
QQQ   357.79 (+0.81%)
AAPL   172.72 (+0.19%)
MSFT   317.06 (+1.17%)
META   304.89 (+1.31%)
GOOGL   134.49 (+1.56%)
AMZN   125.98 (+1.01%)
TSLA   257.97 (+4.64%)
NVDA   436.23 (+0.24%)
NIO   8.71 (+1.16%)
BABA   83.74 (-0.95%)
AMD   102.16 (+2.08%)
T   14.54 (-1.62%)
F   11.90 (-1.41%)
MU   67.68 (-0.22%)
CGC   0.75 (+10.17%)
GE   108.12 (+0.33%)
DIS   78.90 (-0.80%)
AMC   8.18 (+4.20%)
PFE   33.09 (-2.39%)
PYPL   58.15 (+1.48%)
NFLX   374.52 (-0.59%)
NYSE:AMPE

Ampio Pharmaceuticals (AMPE) Competitors

$3.66
-0.02 (-0.54%)
(As of 01:55 PM ET)
Compare
Today's Range
$3.61
$3.80
50-Day Range
$0.26
$5.08
52-Week Range
$3.35
$13.20
Volume
6,669 shs
Average Volume
19,640 shs
Market Capitalization
$2.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AMPE vs. AVTX, SLRX, BLCM, PTPI, ADIL, ATNF, INM, PHIO, UPC, and NBSE

Should you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Avalo Therapeutics (AVTX), Salarius Pharmaceuticals (SLRX), Bellicum Pharmaceuticals (BLCM), Petros Pharmaceuticals (PTPI), Adial Pharmaceuticals (ADIL), 180 Life Sciences (ATNF), InMed Pharmaceuticals (INM), Phio Pharmaceuticals (PHIO), Universe Pharmaceuticals (UPC), and NeuBase Therapeutics (NBSE). These companies are all part of the "pharmaceutical preparations" industry.

Ampio Pharmaceuticals vs.

Ampio Pharmaceuticals (NYSE:AMPE) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations.

Ampio Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Avalo Therapeutics has a consensus price target of $10.00, indicating a potential upside of 7,042.86%. Given Avalo Therapeutics' higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Ampio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Avalo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Ampio Pharmaceuticals has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -146.01%. Avalo Therapeutics' return on equity of 0.00% beat Ampio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A -139.54% -106.90%
Avalo Therapeutics -146.01%N/A -75.99%

In the previous week, Ampio Pharmaceuticals and Ampio Pharmaceuticals both had 2 articles in the media. Ampio Pharmaceuticals' average media sentiment score of 0.79 beat Avalo Therapeutics' score of 0.40 indicating that Ampio Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ampio Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avalo Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

3.1% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.3% of Avalo Therapeutics shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 45.4% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Avalo Therapeutics received 4 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 26.67% of users gave Avalo Therapeutics an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Ampio PharmaceuticalsOutperform Votes
No Votes
Underperform Votes
5
100.00%
Avalo TherapeuticsOutperform Votes
4
26.67%
Underperform Votes
11
73.33%

Ampio Pharmaceuticals has higher earnings, but lower revenue than Avalo Therapeutics. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$16.34M-$20.60-0.18
Avalo Therapeutics$18.05M0.16-$41.66M-$2.14-0.07

Summary

Avalo Therapeutics beats Ampio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.


Get Ampio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMPE vs. The Competition

MetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$2.73M$5.69B$4.33B$14.96B
Dividend YieldN/A2.75%2.51%3.84%
P/E Ratio-0.183.1793.9518.13
Price / SalesN/A142.172,876.568.62
Price / CashN/A21.9590.3015.66
Price / Book0.244.003.826.44
Net Income-$16.34M$198.46M$121.53M$900.18M
7 Day Performance1.09%-2.53%-2.18%-2.59%
1 Month Performance-7.30%-11.70%-8.18%-7.74%
1 Year Performance804.88%1.81%4.80%0.91%

Ampio Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTX
Avalo Therapeutics
1.6233 of 5 stars
$0.14
-17.5%
$10.00
+6,972.1%
-95.7%$2.86M$18.05M-0.0720Gap Down
High Trading Volume
SLRX
Salarius Pharmaceuticals
0 of 5 stars
$0.71
-1.4%
N/A-86.0%$2.57M$1.84M-0.0512Positive News
BLCM
Bellicum Pharmaceuticals
0 of 5 stars
$0.32
-5.9%
N/A-76.0%$3.04M$1.51M0.0013Gap Up
PTPI
Petros Pharmaceuticals
0 of 5 stars
$1.50
-2.6%
N/A-66.1%$3.14M$5.99M0.0024News Coverage
Positive News
ADIL
Adial Pharmaceuticals
1.9185 of 5 stars
$2.61
-8.7%
N/A-69.0%$3.18MN/A-0.3516Positive News
ATNF
180 Life Sciences
0 of 5 stars
$0.60
+1.7%
N/A-95.7%$3.22MN/A0.255Positive News
INM
InMed Pharmaceuticals
1.8032 of 5 stars
$0.69
-2.8%
$45.00
+6,421.7%
-89.1%$2.30M$1.09M-0.0413Positive News
PHIO
Phio Pharmaceuticals
1.8395 of 5 stars
$1.47
+2.1%
$6.00
+308.2%
+153.6%$3.27MN/A0.009Positive News
UPC
Universe Pharmaceuticals
0 of 5 stars
$0.91
-9.0%
N/A-64.9%$3.30M$40.14M0.00224Gap Up
NBSE
NeuBase Therapeutics
1.8382 of 5 stars
$0.94
+9.3%
N/A-90.5%$2.22MN/A-0.0837Gap Up

Related Companies and Tools

This page (NYSE:AMPE) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -